published meta-analysis   sensitivity analysis   studies

azithromycin in COVID-19 severe or critically - Summary of results

RCTOutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOALITION II (Furtado), 2020 1.08 [0.79; 1.47] 1.08[0.79; 1.47]COALITION II (Furtado), 202010%3972 : moderatenot evaluable clinical worseningdetailed resultsCOALITION II (Furtado), 2020 1.36 [0.94; 1.97] 1.36[0.94; 1.97]COALITION II (Furtado), 202010%3972 : moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2020-10-22 10:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 619 - roots T: 290